4 active not recruiting, 3 recruiting, 1 completed, 1 enrolling by invitation. 7 Phase 1, 4 Phase 2, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 7 | Recruiting 3, Active not recruiting 2, Completed 1, Withdrawn 1 |
| Phase 2 | 4 | Active not recruiting 3, Recruiting 1 |
| Phase 3 | 2 | Active not recruiting 1, Enrolling by invitation 1 |
Follow OncoC4, Inc.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety, Pharmacokinetics (PK), and Efficacy of ONC-783 in Advanced Solid Tumors ONC-783 - Advanced Solid Tumor | Phase 1 | Recruiting | OncoC4, Inc. | 20 | 2026-08-10 | 2026-09-08 |
| Gotistobart Long Term Extension (LTE) Study Gotistobart - Advanced Solid Tumor | Phase 3 | Enrolling by invitation | OncoC4, Inc. | 20 | 2026-07-28 | 2026-08-24 |
| Safety, Pharmacokinetics, and Efficacy of AI-081, a Bispecific Antibody for PD-1 And VEGF in Advanced Solid Tumors AI-081 - Advanced Solid Tumor | Phase 1 / Phase 2 | Recruiting | OncoC4, Inc. | 387 | 2025-03-26 | 2026-08-17 |
| Safety, Pharmacokinetics (PK), and Efficacy of ONC 841 in Advanced Solid Tumors ONC-841 - Advanced Solid Tumor | Phase 1 | Recruiting | OncoC4, Inc. | 72 | 2024-08-23 | 2026-06-25 |
| Safety, Tolerability, Immunogenicity and Pharmacokinetics of ONC-841 ONC-841, Placebo - Advanced Solid Tumor | Phase 1 | Withdrawn | OncoC4, Inc. | 2024-06-01 | 2024-04-03 | |
| ONC-392 Plus Lutetium Lu 177 Vipivotide Tetraxetan in Patients With mCRPC ONC-392 low, ONC-392 high, lutetium Lu 177 vipivotide tetraxetan - Metastatic Castration-resistant Prostate Cancer | Phase 1 / Phase 2 | Active not recruiting | OncoC4, Inc. | 148 | 2023-12-11 | 2026-05-22 |
| Safety, PK and Efficacy of AI-061 in Advanced Solid Tumors AI-061 - Melanoma, Non Small Cell Lung Cancer | Phase 1 | Completed | OncoC4, Inc. | 18 | 2023-07-11 | 2026-09-14 |
| ONC-392 Versus Docetaxel in Metastatic NSCLC That Progressed on PD-1/PD-L1 Inhibitors Gotistobart, Docetaxel - Non Small Cell Lung Cancer | Phase 3 | Active not recruiting | OncoC4, Inc. | 630 | 2023-06-28 | 2026-08-13 |
| ONC-392 and Pembrolizumab in Platinum Resistant Ovarian Cancer ONC-392, Pembrolizumab - Ovarian Cancer, High Grade Serous Adenocarcinoma of Ovary | Phase 2 | Active not recruiting | OncoC4, Inc. | 58 | 2022-12-22 | 2026-09-22 |
| Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC ONC-392, Pembrolizumab, Docetaxel - Non Small Cell Lung Cancer, Advanced Solid Tumor | Phase 1 / Phase 2 | Active not recruiting | OncoC4, Inc. | 733 | 2020-09-16 | 2026-09-14 |
Carcinoma, Non-Small-Cell Lung (3) · Carcinoma, Renal Cell (2) · Colorectal Neoplasms (2) · Esophageal Neoplasms (2) · Fallopian Tube Neoplasms (2) · Melanoma (2) · Ovarian Neoplasms (2) · Stomach Neoplasms (2) · Uterine Cervical Neoplasms (2) · Anus Neoplasms (1) · Bile Duct Neoplasms (1) · Breast Neoplasms (1) · Carcinoma, Adenoid Cystic (1) · Carcinoma, Hepatocellular (1) · Carcinoma, Transitional Cell (1)
Docetaxel (2) · pembrolizumab (2) · CD3 Complex (1) · Pluvicto (1)
United States (8) · Australia (3) · Belgium (1) · Canada (1) · China (1) · Germany (1) · Italy (1) · Netherlands (1) · South Korea (1) · Spain (1) · Turkey (Türkiye) (1) · United Kingdom (1)
Kai He, MD, PhD (2) · Tianhong Li, MD, PhD (2) · Bradley Monk, MD (1) · David Wise, MD (1) · Joyce Barlin, MD (1) · Mark Socinski, MD (1) · Mark Stein, MD (1) · Rohit Joshi, MD (1) · Ruth He, MD, PhD (1) · Tianhong Li, MD (1)
2023 (1), R44CA250824 (1)